Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Thumbnail
View/Open
ICR Author
Author
Hall, E
Banerji, U
Type
Journal Article
Metadata
Show full item record
URL
https://repository.icr.ac.uk/handle/internal/3997
Collections
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
Research team
Medicine (de Bono Prostate)
Cancer Biomarkers
Clinical Pharmacology – Adaptive Therapy
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Myeloma Group
Date accepted
2020-07-20
License start date
2020-07-20
Citation
The Lancet Oncology
Publisher
Elsevier